Abstract: The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.

Abstract: A third rail power insulating system, which has a cover board assembly having a support bracket assembly, cover board assembly retaining clips, a side cover board, and a top cover board. The support bracket assembly has a top wall, at least two pairs of top bracket holes with top threads, top bolt supports, a lateral wall, at least three pairs of lateral bracket holes with lateral threads, lateral bolt supports, internal walls, internal reinforcement walls, and a central wall. The side cover board has a plate having a plate top edge and a plate bottom edge, first and second lateral holes, and first and second lateral bolts. The top cover board has an elongated plate, a bottom face having hexagonal cells, first and second top holes, first and second top bolts, and an elongated lip.

Abstract: Combination product for the treatment of neurological and/or psychiatric disorders The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.

Abstract: The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: A system for reversibly converting stadiums into multifunctional infrastructure by removing the pitch and storing it in a pit (6), the pitch having a set of trays (1) having a total length equal to the pitch in a longitudinal direction of the pit, which are moveable, self-supporting and have layers of soil, irrigation and turf; a set of transport trolleys (2) for lifting and moving each tray (1) from its position on the pitch to the pit (6); a set of retractable trellises (5) that can be unfolded on the pit (6), for the entry of each tray (1) from above the pit; an elevator system (8) inside the pit (6) to move each tray to its final position, in storage, or on the pitch; and a storage system (7) for storing each tray in a fixed and stable position.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: A third rail insulator having a head assembly with a channel, and a pedestal assembly. The head assembly and the pedestal assembly are integrated as a single structure to support and isolate a contact rail assembly that supplies power to a transit vehicle. The channel is an open channel that diametrically extends along the upper section of the head assembly. The channel receives the contact rail assembly.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: The present application provides a combination product for the treatment and/or prevention of psychiatric and/or neurological disorders. The combination product comprises (i) a compound which promotes neurogenesis and has hallucinogenic and/or psychedelic side effects, and (ii) a 5-HT2A receptor antagonist which alleviates and/or removes the hallucinogenic and/or psychedelic side effects caused by the first compound.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: Provided are novel purine nucleoside/nucleotide analogues compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.

Abstract: Systems and methods are disclosed herein relating to a momentary contact switch that can be both manually and electronically actuated. In some embodiments, an electronic module can be added to a manual momentary contact switch to enable electronic control. The momentary contact switch can be transitioned between first, second, and third electrical states based on the rotation of a shaft between first, second, and third rotational positions. Rotary arms are selectively engaged by pull arms connected to a master solenoid to selectively rotate the shaft from the first rotational position to the second and third rotational positions.

Abstract: An apparatus includes a radio frequency (RF) feed and an extruded member made of metal and coupled to the RF feed. The extruded member includes a first surface that includes a first slot having a first width and a first length, and a second slot having a second width and a second length. The second width is at least 1.2 times greater than the first width. The second slot intersects the first slot at an angle with respect to the first slot that is between 70 and 110 degrees.

Abstract: Systems and methods are disclosed herein relating to a momentary contact switch that can be both manually and electronically actuated. In some embodiments, an electronic module can be added to a manual momentary contact switch to enable electronic control. The momentary contact switch can be transitioned between first, second, and third electrical states based on the rotation of a shaft between first, second, and third rotational positions. Rotary arms are selectively engaged by pull arms connected to a master solenoid to selectively rotate the shaft from the first rotational position to the second and third rotational positions.

Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.

Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.

Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the ?-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of ?-amyloid aggregates.